Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

Stay informed on the project!

News
6 December 2024

PANCAID is Now on Bluesky

Exciting news! PANCAID has officially joined the social media platform Bluesky, a fresh and dynamic space for connecting and sharing ideas.

By expanding our digital presence, we aim to reach more individuals passionate about early cancer detection and cutting-edge research in pancreatic cancer. Whether you’re a researcher, patient advocate, or simply curious about our work, Bluesky offers a new way to stay informed and engaged.

Follow us @pancaid.bsky.social or https://bsky.app/profile/pancaid.bsky.social for updates, insights, and conversations about how we’re advancing this research field.

Not on Bluesky? You can also connect with us on LinkedIn, Twitter / X, or Instagram.

News
21 November 2024

World Pancreatic Cancer Day

On this World Pancreatic Cancer Day, PANCAID members engaged in a variety of events!

  • UKE hosted an event “Hello Pankreas!” at the UKE in Hamburg, Germany
  • KI hosted the Pancreatic Cancer Congress, Karolinska Institutet (PanCKI) in Stockholm, Sweden
  • PCE attended the European Cancer Summit in Brussels, Belgium

Event
15 January 2025

Save the date: PANCAID’s Stakeholder Dialogue Event

We’re excited to announce the Save-the-Date for PANCAID’s first Stakeholder Dialogue Event!
When? 15th January 2025
Where? Brussels, Belgium
This event is a collaboration between PANCAID, Pancreatic Cancer Europe (PCE), and United European Gastroenterology (UEG)!

About

PANCAID is an international research consortium aiming to develop a minimally invasive blood test using liquid biopsy to detect pancreatic cancer to facilitate early detection of the cancer and its precursors. With 16 partners + 1 associated partner from eight countries, the project has received funding for five years to potentially revolutionize current pancreatic cancer diagnosis methods and improve patient outcomes.

Learn More

Our vision

PANCAID strives to provide a minimally invasive blood test using a comprehensive panel of liquid biopsy diagnostics (LBx) for early detection of pancreatic cancer and its precursor lesions.

Read on

Why it matters

Pancreatic cancer is a malignant neoplasm that originates in the cells of the pancreas, an organ located in the abdominal cavity behind the stomach. It is known to be one of the most aggressive and deadly types of cancer, with a high mortality rate. Pancreatic cancer is often difficult to detect in its early stages, as it tends to show minimal or no symptoms until it reaches advanced stages. This makes it challenging to diagnose and treat, and contributes to its poor prognosis.

Discover more